article thumbnail

Could long Covid’s signs of immune dysregulation in the blood lead to a diagnostic test?

STAT

Not knowing what triggers its persistent and distressing symptoms makes the condition challenging to treat; it’s hard to even say definitively who has it. Long Covid has long eluded scientists looking for its cause.

article thumbnail

How long should immune checkpoint inhibitor therapy be used in non-small cell lung cancer?

Hospital Pharmacy Europe

Immune checkpoint inhibitors have transformed the management of non-small cell lung cancer, but how long should treatment be continued for optimal survival? It has long been recognised that a hallmark of cancer is immune evasion and that the immune system is held back by inhibitory immune checkpoint receptors and ligands.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vertex to acquire Alpine Immune Sciences for $4.9bn

Pharmafile

Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share, totaling an approximate $4.9bn. Alpine’s lead […] The post Vertex to acquire Alpine Immune Sciences for $4.9bn appeared first on Pharmafile.

article thumbnail

4th Antigen Specific Immune Tolerance Summit

pharmaphorum

The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. This is the industry’s definitive antigen specific drug development forum.

article thumbnail

Triple Negative Breast Cancer Drug Development Digital Summit

pharmaphorum

Given the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summi t has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint, DDR inhibitor, ADC and other novel agents.

article thumbnail

Gilead to acquire MiroBio for $405 million

European Pharmaceutical Review

Gilead Sciences has signed a definitive agreement to acquire outstanding share capital of clinical-stage biotechnology company MiroBio for around $405 million. MB272 targets T, B and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response. . “We

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Verily’s Immune Profiler can, Kim asserted, “generate more than 8 million immune measures across 24 immune cell subsets”.